Miravo Healthcare: Marketing Resultz Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

• Miravo Healthcare 2022 revenue: $482 million (Exhibit 1).
• Resultz product line net revenue contribution: $18.4 million (Exhibit 2).
• Marketing spend for Resultz: $4.2 million, representing 22.8% of product revenue (Exhibit 3).
• Customer Acquisition Cost (CAC) for Resultz: $142 per lead, up from $118 in 2021 (Exhibit 4).
• Average Revenue Per User (ARPU) for Resultz: $310 (Exhibit 2).

Operational Facts

• Product: Resultz is a diagnostic monitoring software targeted at primary care physicians.
• Current Sales Model: Direct sales force (45 representatives) supported by digital lead generation.
• Market Position: Third in market share (14%) behind MedTech Solutions (38%) and Diagnostic Pro (26%).
• Infrastructure: Existing CRM integration with legacy EMR systems is cited as a primary friction point for new client onboarding (Paragraph 14).

Stakeholder Positions

• Sarah Jenkins (VP of Marketing): Advocates for doubling digital marketing spend to $8.4M to drive lead volume.
• Marcus Thorne (CFO): Demands a reduction in CAC to below $120 before approving further budget increases.
• David Chen (Head of Sales): Argues that current leads are low-quality; claims conversion rate has dropped from 12% to 7% (Paragraph 22).

Information Gaps

• Churn rate for Resultz clients is not explicitly provided, only new acquisition data.
• Specific breakdown of digital versus offline lead quality is absent.
• Competitor pricing strategies for the upcoming 2024 fiscal year are estimated rather than verified.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

How can Miravo Healthcare stabilize the Resultz unit economics while maintaining market share in an increasingly saturated diagnostic monitoring segment?

Structural Analysis

• Competitive Rivalry: High. MedTech Solutions uses bundling strategies that Miravo cannot match without eroding margins.
• Buyer Power: High. Primary care practices face budget constraints and prioritize EMR compatibility over advanced features.

Strategic Options

• Option 1: Aggressive Digital Expansion. Increase spend to $8.4M. Rationale: Capture market share quickly. Trade-offs: Increases CAC; requires high conversion efficiency.
• Option 2: Sales-Led Optimization. Freeze marketing spend; reallocate funds to sales training and CRM integration support. Rationale: Improves conversion rate of existing leads. Trade-offs: Slows growth; risks losing ground to competitors.
• Option 3: Targeted Niche Focus. Pivot marketing spend toward high-density urban practices with existing EMR compatibility. Rationale: Lowers CAC by increasing conversion probability. Trade-offs: Limits total addressable market size.

Preliminary Recommendation

Pursue Option 3. The current CAC trend is unsustainable. Focusing on high-conversion segments allows for margin protection while fixing the underlying integration friction that hampers sales.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

• Phase 1 (Days 1-30): Segment analysis to identify top 20% of high-conversion practices.
• Phase 2 (Days 31-60): Redirect marketing assets to target these segments; implement CRM-EMR integration patch.
• Phase 3 (Days 61-90): Sales team training on new segment-specific value propositions.

Key Constraints

• Technical Debt: The legacy EMR integration is the primary bottleneck. If the patch fails, conversion rates will remain suppressed regardless of marketing quality.
• Sales Alignment: The sales force is currently demoralized by low-quality leads. Success requires immediate cultural buy-in.

Risk-Adjusted Implementation

Contingency: If conversion rates do not improve by 15% within 60 days, pause all paid acquisition and shift entirely to account-based marketing for existing high-value clients.

4. Executive Review and BLUF (Executive Critic)

BLUF

Miravo Healthcare is attempting to solve a product-market fit problem with a marketing budget increase. This is an error. The declining conversion rate (12% to 7%) indicates that Resultz is losing its competitive edge or failing to integrate with modern EMR systems. Doubling marketing spend will only accelerate the burn rate of capital without addressing the root cause: an inferior user experience compared to larger incumbents. The firm must pivot to a retention-based, high-compatibility strategy focused on existing high-density accounts. Abandon the volume-based acquisition model immediately.

Dangerous Assumption

The assumption that marketing lead volume is the primary driver of revenue. Evidence suggests the sales funnel is broken due to product friction, not lead quantity.

Unaddressed Risks

• Product Obsolescence: The case ignores the likelihood that the software is technically outclassed by MedTech Solutions, rendering marketing spend effectively wasted.
• Sales Force Attrition: Continued focus on low-quality leads will result in the loss of top-performing sales representatives who cannot hit their quotas.

Unconsidered Alternative

Strategic Partnership: Instead of competing, Miravo should pursue an OEM agreement with MedTech Solutions to integrate Resultz as a feature within their platform, pivoting from a standalone product to a service layer.

Verdict: REQUIRES REVISION. The strategy must reconcile the product-market fit gap before any further marketing spend is authorized.